Latest Breaking News On - Tisch cancer institute - Page 1 : comparemela.com

Dr Jagannath on Linvoseltamab vs Teclistamab in Triple-Class–Exposed R/R Myeloma

Dr Jagannath on Linvoseltamab vs Teclistamab in Triple-Class–Exposed R/R Myeloma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Sundar-jagannath
Tisch-cancer-institute
Multiple-myeloma
Mount-sinai

ASCO 2024: Using Molecular Testing to Guide Perioperative Systemic Therapy for Urothelial Cancer

ASCO 2024 molecular testing to guide perioperative systemic therapy for urothelial cancer, ctDNA testing, adjuvant immune checkpoint blockade, TOMBOLA trial.

United-states
Georgia
New-york
Chicago
Illinois
American
Tom-powles
Mattd-galsky
Zachary-klaassen
Matt-galsky
American-society-of-clinical-oncology
Icahn-school-of-medicine-at-mount-sinai

Frontline Nivolumab/Chemo Approved in Europe for Unresectable or Metastatic Urothelial Cancer

The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.

Netherlands
New-york
United-states
Matthew-galsky
Tisch-cancer-institute-of-mount-sinai
Netherlands-cancer-institute
Bristol-myers-squibb
European-commission
Tisch-cancer-institute
Mount-sinai
Myers-squibb

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Sundar-jagannath
Oncologic-drugs-advisory-committee
Tisch-cancer-institute
Multiple-myeloma
Mount-sinai
Drugs-advisory-committee

Dr Jagannath on the ODAC Meeting on the Safety of Cilta-Cel in R/R Multiple Myeloma

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.

Sundar-jagannath
Oncologic-drugs-advisory-committee
Tisch-cancer-institute
Multiple-myeloma
Mount-sinai
Drugs-advisory-committee
The-tisch-cancer-institute-at-mount-sinai
Onclive-tv
Multiple-myeloma